Become Affiliate

PepFlow

Download

The Amylin Signal

Cagrilintide

A long-acting amylin analog studied alone and with semaglutide for weight management and metabolic outcomes.

Weight loss
TierA
EvidenceStrong
SafetyModerate Data
FDA statusNot Approved
Last reviewed October 25, 2026 38 citations How to read these labels

What is Cagrilintide?

Cagrilintide is an amylin analog. Amylin is a pancreatic hormone involved in satiety and gastric-emptying biology, so cagrilintide sits beside incretin drugs rather than inside the GLP-1 family.[4]

As monotherapy, cagrilintide has phase 2 dose-finding evidence for weight management. Its most visible development path is co-administered cagrilintide plus semaglutide, often called CagriSema.[4][5][6]

Recent REDEFINE publications strengthen the human evidence for CagriSema. Cagrilintide-alone and CagriSema results should stay separate because the combination includes semaglutide.[7][8][5]

What Cagrilintide is investigated for

Cagrilintide evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Semaglutide combination weight loss

Injectable

78%Moderate

Combination weight loss is the most visible CagriSema use case, but the combination remains separate from cagrilintide monotherapy and regulatory approval status.[7][3][2]

Human evidence

CagriSema studies show larger weight-loss effects when cagrilintide is coadministered with semaglutide in adults with overweight or obesity.[5][7][9]

Animal / mechanistic evidence

The rationale combines amylin/calcitonin receptor signaling from cagrilintide with GLP-1 receptor signaling from semaglutide.[17][19][15]

Monotherapy weight reduction

Injectable

70%Moderate

Cagrilintide monotherapy has human weight-management evidence, while the largest effects currently come from the semaglutide combination program.[4][14][1]

Human evidence

A phase 2 dose-finding study supports once-weekly cagrilintide monotherapy for body-weight reduction in people with overweight or obesity.[4][12]

Animal / mechanistic evidence

Amylin analog activity supports satiety and energy-balance biology, complementing but not requiring GLP-1 pathway biology.[19][17][30]

Type 2 diabetes glycemic control

Injectable

66%Moderate

Type 2 diabetes glycemic control is a CagriSema combination use case, not evidence that cagrilintide alone is an approved diabetes therapy.[8][1]

Human evidence

CagriSema has human trial evidence in type 2 diabetes with obesity or overweight, including weight and glycemic endpoints.[6][8]

Animal / mechanistic evidence

The glycemic component is strongly influenced by semaglutide, so this should be read as combination evidence.[6]

Appetite control and satiety

Injectable

49%Preliminary

Satiety is a plausible cagrilintide effect within weight management, but it should not be framed as a standalone approved use.[4][15]

Human evidence

Human weight-management studies are consistent with a satiety-driven effect, but they mainly report body-weight change rather than direct day-to-day appetite endpoints.[4][5]

Animal / mechanistic evidence

Mechanistic studies link cagrilintide to amylin and calcitonin receptor pathways, including brain amylin receptor signaling involved in energy balance.[19][17][30]

Evidence snapshot

82%

Human evidence

Strong

Human evidence includes cagrilintide monotherapy dose-finding, cagrilintide plus semaglutide studies, type 2 diabetes combination data, and published REDEFINE results.[4][5][6][7][8]

68%

Animal / preclinical

Moderate

Preclinical and receptor-mechanism research supports amylin and calcitonin receptor biology, but the practical confidence comes from human weight-management trials.[30][19][17]

80%

Mechanism support

Strong

Amylin-analog activity gives a coherent rationale for satiety and body-weight effects, and combination trials pair that biology with semaglutide rather than replacing GLP-1 signaling.[4][5][17]

Forms & administration

Cagrilintide is an investigational subcutaneous medicine, with a cartridge presentation for NovoPen 4. Cagrilintide alone and cagrilintide–semaglutide combinations have separate dosing contexts. The device name does not identify its contents, cartridge strength or preparation requirements.[4][5][7][38]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Doses range from 0.3-4.5 mg once weekly. Combination protocols use 2.4 mg cagrilintide with 2.4 mg semaglutide.[4][5][7][8]

Timing Considerations

Use the same injection day each week.[4][5][10]

Cycle Length

Treatment is long term, commonly lasting 6-16 months.[4][10][11][7]

What to expect

First weeks

Fullness can come sooner and appetite may be easier to manage, especially when cagrilintide is paired with semaglutide.[5][4]

3-6 months

Weight and waist reductions can become more visible as fullness and appetite control build, with larger effects in cagrilintide-semaglutide combination data.[4][7]

1 year

Weight and waist reductions can persist with continued treatment, especially in combination studies, while appetite control remains the main felt effect.[7][8]

After stopping

Fullness may fade and appetite can move back toward baseline after pausing or stopping; weight and waist changes may soften without ongoing amylin-analog exposure.[4][15]

Safety profile

Cagrilintide safety is still investigational and route-specific. The practical safety focus is GI tolerability, combination effects with semaglutide, hypoglycemia considerations in diabetes trials, and the lack of approved-product labeling.[4][6][3]

Common side effects

Cautions

  • No FDA label[1][3]
  • Semaglutide, GLP-1, or other satiety drugs[5][7]
  • Pregnancy and special populations[10][1]

What we don't know

Rare events, long-term use, discontinuation effects, and special-population safety remain unsettled while cagrilintide and CagriSema development continues.[10][11]

Who Cagrilintide is not for

Route-specific avoid and medical-review notes:

  • Pregnancy and special populations

    Until approved labeling exists, pregnancy, breastfeeding, pediatric use, frailty, and complex endocrine disease should be treated as trial-exclusion-level concerns.[10][1]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Semaglutide, GLP-1, or other satiety drugs

    Cagrilintide adds amylin-pathway satiety effects on top of GLP-1 therapy; pairing it with semaglutide or other GLP-1, GIP, or amylin weight-loss drugs can compound nausea, vomiting, diarrhea, constipation, and appetite-suppression effects, and safety rules outside studied cagrilintide-semaglutide protocols are not established.[5][7]

Pairing notes

Works well with

Semaglutide as GLP-1 partnerInjectable

Semaglutide activates GLP-1 pathways that reduce appetite and slow gastric emptying, while cagrilintide activates amylin pathways that increase satiety. Together they provide complementary appetite-control signals.[5][7]

Not recommended with

Tirzepatide: appetite-pathway overlapInjectable

Cagrilintide adds amylin-mediated satiety to tirzepatide's GIP and GLP-1 effects. This combination falls outside studied CagriSema and has no established combined dosing or safety framework.[7][35]

Retatrutide: appetite-pathway overlapInjectable

Cagrilintide adds amylin-mediated satiety to retatrutide's GIP, GLP-1, and glucagon effects. The combination is investigational and has no established combined dosing or safety framework.[7][36][37]

How it works

Cagrilintide is a long-acting amylin analog. Its core mechanism is satiety signaling, not GLP-1 duplication, with brain amylin-receptor pathways supporting food-intake reduction. That keeps it in amylin/satiety context.[28][19]

Cagrilintide-alone data show the amylin pathway can move body weight, while CagriSema pairs that pathway with semaglutide's GLP-1 appetite, gastric-emptying, and glucose effects.[4][5][7]

Combination results still belong to the combination: weight loss, nausea, appetite suppression, and tolerability in CagriSema trials cannot be assigned cleanly to cagrilintide alone or generalized to other amylin drugs.[5][7]

Research gaps & open questions

What the current literature has not yet settled about Cagrilintide:

01

Regulatory review and approved labeling are still needed to define safe dosing, warnings, contraindications, manufacturing standards, and real-world use.[1][3]

02

Trials need to separate cagrilintide's effects from semaglutide's effects; results from CagriSema should not be treated as proof for cagrilintide alone.[4][7]

03

Longer studies should show what happens during maintenance and after stopping, including changes in muscle mass and risks involving the gut, gallbladder, diabetes medications, and understudied populations.[10][11]

Common questions

Is cagrilintide a GLP-1 drug?

No. Cagrilintide is an amylin analog. It is often discussed with semaglutide because CagriSema combines amylin and GLP-1 pathways.[4][5]

Is CagriSema FDA-approved?

No. CagriSema is not FDA-approved for human use as a drug product in the United States.[3][2]

Can CagriSema results be used as cagrilintide-alone results?

No. CagriSema includes semaglutide, so the efficacy and safety profile belongs to the combination.[7][8]

Myths & misconceptions

Myth

Amylin analogs and GLP-1 agonists are the same kind of peptide.

Reality

They are both satiety-related metabolic therapies, but they target different hormone pathways.[4][5]

Myth

CagriSema results prove cagrilintide alone works the same way.

Reality

Combination studies include semaglutide, so they cannot be used as cagrilintide-alone proof.[7]

History & discovery

Cagrilintide's history starts in long-acting amylin-analog development, not GLP-1 development. It became prominent because CagriSema paired cagrilintide's satiety biology with semaglutide's GLP-1 biology, a distinction that now dominates public attention.[28][26][4][5]

Development, dose-finding, and early cagrilintide-plus-semaglutide work positioned cagrilintide as an amylin satiety drug with a separate rationale from GLP-1 therapy before larger combination trials.[28][4][5]

Type 2 diabetes, REDEFINE, and mechanistic publications made the CagriSema program the main public evidence anchor while keeping combination results separate from cagrilintide-alone claims and informal stacking.[6][7][8][19]

Published research38 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your weight-management goals.

Use PepFlow to record your Cagrilintide protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00